Posters & Publications 2017 BIO103, a drug candidate for the treatment of muscle wasting disorders. Serova et al. Oral and poster presentations at the 10th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 8-10, 2017, Rome, Italy. Abstract published in Journal of Cachexia, Sarcopenia and Muscle, 8, 1067-1068. Abstract 8-09. SARA clinical program for evaluating safety and…
Details
Posters & Publications 2018 BIO101 accelerates differentiation and enhances mitochondrial function in skeletal muscle cells. Serova et al. Oral presentation at the 11th international SCWD conference on cachexia, sarcopenia and muscle wasting, December 7-9, 2018, Maastricht, Netherlands. Abstract published in Journal of Cachexia, Sarcopenia and Muscle 2018; 9; 1170. Abstract 4-11. Transitioning from SARA-OBS, an observational study to SARA-INT, a double-blind,…
Details
POSTERS & PUBLICATIONS 2019 SARA program: preliminary findings from SARA-OBS study and impacts on the SARA-INT study design. Dioh et al. Oral presentation at SCWD conference on cachexia, sarcopenia and muscle wasting. December 6-8th, Berlin, Germany Abstract published in Journal of Cachexia, Sarcopenia and Muscle Preclinical characterization of Sarconeos (API BIO101) in Duchenne muscular…
Details
Posters & Publications 2022 Structural Analysis of Unstable Norbixin Isomers Guided by Pure-Shift Nuclear Magnetic Resonance. Bertho G., Oumezziane I.E., Caradeuc C., Guibout L., Balducci C., Dinan L., Dilda P.J., Camelo S., Lafont R., Giraud N. Article published in Magn. Reson. Chem. 60(5), pp. 504–514 2021 A2E-induced inflammation and angiogenesis in RPE cells in vitro…
Details
Posters & Publications 2023 COVA clinical study: Results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy and safety of Ruvembri in hospitalized severe COVID-19 patients. Poster presented at European Respiratory Society 21st Lung Science Conference, 9–12 March 2023, Estoril, Portugal COVA study: results from a double-blind, placebo-controlled phase 2/3 study to assess efficacy…
DetailsDUCHENNE MUSCULAR DYSTROPHY: MYODA CLINICAL PROGRAMME 1. A rare genetic disease with limited treatment options Duchenne muscular dystrophy (DMD) is a rare genetic disease affecting 1 in 5,000 boys at birth, or 220,000 people worldwide. It is characterised by accelerated muscle degeneration, leading to loss of mobility, respiratory failure and cardiomyopathy, with premature death…
Details